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Polysaccharide A (PSA), the archetypical immuno-
modulatory molecule of the gut commensal Bacter-
oides fragilis, induces regulatory T cells to secrete
the anti-inflammatory cytokine interleukin-10 (IL-
10). The cellular mediators of PSA’s immunomodu-
latory properties are incompletely understood. In a
mouse model of colitis, we find that PSA requires
both innate and adaptive immune mechanisms to
generate protection. Plasmacytoid DCs (PDCs)
exposed to PSA do not produce proinflammatory cy-
tokines, but instead they specifically stimulate IL-10
secretion by CD4+ T cells and efficiently mediate
PSA-afforded immunoprotection. PSA induces and
preferentially ligates Toll-like receptor 2 on PDCs
but not on conventional DCs. Compared with other
TLR2 ligands, PSA is better at enhancing PDC
expression of costimulatory molecules required for
protection against colitis. PDCs can thus orchestrate
the beneficial immunoregulatory interaction of com-
mensal microbial molecules, such as PSA, through
both innate and adaptive immune mechanisms.
INTRODUCTION
Studies in animal models and patients show that oral antigen
administration represents a highly tolerogenic route linked to
the gut and its associated lymphoid tissues, sites presumably
rich in commensal microbes with immunomodulatory molecules
and in immune cells with regulatory potential (Pabst and Mowat,
2012). Since commensal microbes have immunoregulatory
capacities, the microbiota is viewed as important in inducing a
tolerogenic outcome when an antigen encounters the immune
system. In the few commensal-immune associations known to
cause immunoregulation, some microbes have been identified
at the genus (or, uncommonly, the species) level, but little
information has been obtained at the microbial molecular level
(Atarashi et al., 2011, 2013; Hall et al., 2008; Smith et al.,
2013). An exception is capsular polysaccharide A (PSA) of the
gut commensal Bacteroides fragilis, which induces regulatoryCellT cells (Tregs) to secrete the potent anti-inflammatory cytokine
interleukin-10 (IL-10), thereby limiting pathologic inflammation
in the gut and more distant tissues (e.g., brain) (Mazmanian
et al., 2008; Ochoa-Repa´raz et al., 2010; Round andMazmanian,
2010).
In the absence of antigen-presenting cells (APCs), PSA-
induced IL-10 secretion by CD4+ T cells in vitro depends on
Toll-like receptor 2 (TLR2) (Round et al., 2011). We hypothesized
that this direct PSA-T cell interaction may not suffice for immu-
noprotection and that APCs may be necessary. Studies using
PSA-containing outer membrane vesicles from B. fragilis rather
than purified PSA showed that adoptively transferred dendritic
cells (DCs) confer PSA-specific immunoprotection, whereas
those from PSA-depleted B. fragilis do not (Shen et al., 2012).
Outer membrane vesicles contain immunostimulatory molecules
other than PSA, e.g., lipopolysaccharide (LPS), lipids, and mem-
brane proteins. We asked whether purified PSA can induce
tolerogenic properties in DCs and, if so, whether these DCs
are required for immunoprotection in vivo.
Tolerogenic DCs are a major functional class of APCs influ-
encing Tregs (Steinman et al., 2003). Their exact characteristics,
including subset phenotype, vary with the inflammatory setting
(Maldonado and von Andrian, 2010). Two broad DC categories
thought to be distinct in transcriptional control of DC lineage
commitment and function are conventional DCs (CDCs) and
plasmacytoid DCs (PDCs) (Miller et al., 2012; Young et al.,
2008). Using purified PSA as a prototypical commensal microbial
molecule, we compared tolerogenic potential of DC subsets
against inflammation-induced pathologic outcomes. We found
a vital role for PDCs in PSA-mediated induction of tolerance
and immunoprotection. Our findings raise the possibility of
PDC use in commensal-based immunoregulatory therapies.RESULTS
DC-Dependent Augmentation of IL-10 Production
in CD4+ T Cells by PSA In Vitro
Weused primary splenic DC-CD4+ T cell coculture to investigate
DC relevance in PSA-mediated IL-10 augmentation (Figure 1A).
Only in the presence of DCs did CD4+ T cells from wild-type
(WT) mice yield significant amounts of IL-10. The yield was sig-
nificantly greater with than without PSA. Coculture of DCs with
CD4+ T cells from IL-10/ mice showed that CD4+ T cellsHost & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inc. 413
Figure 1. PSA-Stimulated IL-10 Secretion by CD4+ T Cells in Splenic
DC-CD4+ T Cell Coculture Is Dependent on DCs
(A) IL-10 levels in culture supernatants (asmeasured by ELISA) are significantly
higher in wells with PSA than in wells without PSA and suggest DC depen-
dence of IL-10 secretion by CD4+ T cells. Error bars indicate SEM values.
Data represent the average of four independent experiments analyzed by
Student’s t test. ***p < 0.001; n.d., not detected; ns, not significant.
(B) In cocultures with IL-10/ CD4+ T cells and WT DCs, but not with WT
CD4+ T cells and IL-10/ DCs, essentially no IL-10 is produced; thus, the
major source of IL-10 in these cocultures is CD4+ T cells. n.d., not detected.
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an APC requirement for IL-10 production by CD4+ T cells and
differed from those obtained by different methodology (Round
et al., 2011). We set out to determine whether PSA-mediated
immunoregulation of inflammatory diseases requires DC help
and, if so, to identify the required DC subset.
PDCs Are Linked with PSA-Mediated Protection in
TNBS-Induced Colitis
Mesenteric lymph nodes (MLNs), the major gut-draining lymph
nodes, are immunologically affected by orally delivered antigens
(Pabst and Mowat, 2012; Spahn et al., 2001; Worbs et al., 2006)
and are a potential site of DC-CD4+ T cell interaction after PSA
oral gavage. We reported that fluorescently labeled PSA given
by oral gavage is associated with CD11c+ DCs but not CD4+
T cells in MLNs (Mazmanian et al., 2005). To characterize the
role of DC subsets in PSA-mediated immunoregulation, we
studied these cells in MLNs during 2,4,6-trinitrobenzenesulfonic
acid (TNBS)-induced colitis. Before giving TNBS intrarectally, we
pretreated mice by gavage with PSA or PBS. First we counted
absolute PDC and CDC numbers with phenotypic markers
and Flow-Count Fluorospheres. During inflammation, we used
the marker Siglec H (SH, an I-type lectin receptor expressed
with high fidelity on PDCs) (Swiecki and Colonna, 2010; Zhang
et al., 2006) to follow PDCs (Figures S1A and S1B).
At peak inflammation, PDC numbers were drastically reduced
in MLNs of diseased mice (the TNBS + PBS group) from counts
in controls (no TNBS), while CDC numbers were minimally
affected in MLNs. At the inflammation apex, PDC numbers in
MLNs of PSA-pretreated mice (the TNBS + PSA group) but not
of the diseased group were nearly normal (Figures 2A and 2B).
PDC immunomodulation during disease was not seen in colonic
LP. However, PSA significantly increased PDC numbers without
significantly altering CDC numbers from those in TNBS + PBS
mice (Figures S1C and S1D). Given the clear modulation
of PDCs in lymphoid and gut tissues of PSA-pretreated mice,
we investigated whether PDCs were directly associated with
PSA’s immunoprotective action.414 Cell Host & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier InIn MLNs, both PDC frequency and SH expression (measured
as mean fluorescence intensity) were significantly lower in
TNBS + PBS mice than in mice not given TNBS. In contrast,
TNBS + PSA mice had significantly higher PDC frequency and
SH expression than TNBS + PBS mice (Figures 2C and S1E).
In addition to affecting PDC numbers, PSA maintained immune
status at preinflammatory levels, as assessed by PDC frequency
and SH expression. Both of the latter parameters were signifi-
cantly but inversely correlated with cumulative colitis scores
(Figures 2D and S1F), results strongly supporting a role for
PDCs in immunoprotection.
Depletion of PDCs Abrogates PSA-Mediated Protection
against TNBS-Induced Colitis
To determine whether PDCs are required for PSA-mediated pro-
tection, we depleted PDCs by treating BDCA2-DTR mice—i.e.,
human diphtheria toxin receptor (DTR) transgenic mice express-
ing DTR under the blood DC antigen 2 (BDCA2) promoter—with
diphtheria toxin (DT). This approach has been validated for
specificity of PDC depletion (Swiecki et al., 2010). We verified
that DT treatment of BDCA2-DTR mice depletes PDCs in
MLNs and spleen (Figure S2B). PSA-treated controls not given
DT were protected. However, specific PDC removal by DT treat-
ment rendered PSA-mediated protection insignificant (Figure 3).
As an alternative approach of PDC depletion, we treated
mice with monoclonal antibodies (mAbs) to PDCA-1 on each of
the 2 days before intrarectal TNBS administration (Figure S2A).
In addition to clinical and pathologic scores, we used CD11b+
CD11c cell frequency in colonic LP as a cellular correlate of
pathology. We found a significant direct correlation between
cell counts and colitis scores (Figures S2C and S2D). A patho-
genic role for similar cells in TNBS colitis has been described
(Kanai et al., 2001; Leon et al., 2006; Palmen et al., 1995). Among
diseased mice not treated with PSA, neither cumulative disease
score nor accumulation of potentially pathogenic CD11b+
CD11c cells in the colon after mAb treatment differed from
values in isotype controls. These results suggest that PDCs do
not play a pathogenic role in this colitis model. Values for both
parameters (disease score and CD11b+CD11c cell counts)
were significantly lower in PSA-treated mice than in controls.
However, PSA did not protect mice or reduce CD11b+CD11c
cell frequency when PDCs were depleted with mAbs (Figures
S2E–S2G). Despite concern about the anti-PDCA-1 approach
(i.e., PDCA-1 is expressed during inflammation on cells other
than PDCs) (Swiecki and Colonna, 2010), our very similar results
with BDCA2-DTR mice support a requirement for PDCs in vivo
in PSA-mediated immunoregulation.
We used the experimental autoimmune encephalomyelitis
(EAE) model to validate PDCs’ immunoregulatory role, assessing
PSA-mediated immunoprotection at a site distant from the
gut. We induced EAE in four groups of SJL/J mice with myelin
proteolipid protein (PLP) and adjuvant; PSA is protective in this
model (Ochoa-Repa´raz et al., 2010). Two groups received a
mAb to PDCA-1 to deplete PDCs. One of these groups also
received PSA; the other received PBS. The remaining two
groups were given isotype control IgG. One of these groups
also received PSA and the other PBS. In the two groups given
mAb to PDCA-1, 15 of 16 mice died on day 7, irrespective of
PSA treatment. These deaths preceded clinical symptom onset,c.
Figure 2. PDCs Exhibit a Protective Pheno-
type in TNBS-Induced Colitis after PSA Pre-
treatment
(A) Mice treated with PSA orally (100 mg/dose,
TNBS+PSA) before intrarectal challenge with
TNBS in a colitis model had a significantly greater
(8.52-fold) increase in PDC numbers in MLNs
than did mice pretreated with PBS (TNBS + PBS).
Each dot represents one mouse on day 3 after
TNBS or control buffer administration. PDCs were
identified by gating of SH+CD11bB220+CD11c+
cells.
(B) Numbers of CDCs (CD11bB220+ population
gated out from CD11c+ population) in MLNs
were not significantly changed in disease or in
PSA-treated mice.
(C) Augmentation of PDC frequency in MLNs
after TNBS challenge (% of SH+ PDCs in the
CD11bB220+CD11c+ population) was signifi-
cantly greater in mice pretreated with oral PSA
(50 mg/dose) than in PBS-treated mice.
(D) In TNBS colitis, SH+ PDC frequency in MLNs
is significantly but inversely correlated with colitis
scores. Horizontal bars in scatter plots represent
median values. Unpaired Student’s t test: *p <
0.05; **p < 0.01; ***p < 0.001; ns, not significant.
See also Figure S1.
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age was visually detectable (Figure S2H). The one surviving
mouse in the group given PSA and PDCA-1 mAb developed
disease on day 12. In contrast, early deaths occurred among
PDCA-1 mAb-treated mice, but not isotype control IgG-treated
mice (Figure S2H). The mortality rate was higher, clinical symp-
toms developed earlier, and EAE scores indicated more severe
disease in mice given PBS and isotype control (Figures S2H–
S2J) than in counterparts given PSA and isotype control. Thus,
PDCs are critical to PSA-mediated immunoprotection in the
gut and distant tissues. We could not use the DT approach to
investigate EAE because DT is toxic to WT mice when given
during EAE induction (Meyer Zu Ho¨rste et al., 2010).
PSA-Pretreated PDCs, but Not CDCs, Confer Protection
after Adoptive Transfer
To establish a mechanistic role for PDCs in PSA-mediated
immunoregulation, we first investigated whether PSA-treated
DCs confer protection by adoptive transfer in the TNBS-induced
colitis model. We used bone marrow-derived DCs (BMDCs)
enriched with CD11c microbeads. After isolation, DCs from WT
mice were cultured with or without PSA, washed, and adoptively
transferred to mice of the same background. Two DC doses
(1–1.5 3 105 and 6–6.5 3 105, administered twice) were used.
After intrarectal TNBS administration, mice adoptively receiving
in vitro PSA-treated DCs had significantly lower cumulative clin-
ical scores, with a dose-response trend, than mice receiving
PBS-treated DCs. The median colitis score in TNBS + PSA
controls was similar to that in mice given the higher dose of
PSA-treated DCs (Figures 4A and 4B). To compare PDC and
CDC efficiency in protection against TNBS colitis, we comparedCelladoptive transfer of relatively few (1–1.5 3 105) bone marrow-
derived PDCs (BMPDCs) and CDCs after incubation with PSA
or PBS. In contrast to PBS-pretreated PDCs, PSA-pretreated
PDCs offered significant protection, whereas this dose of PSA-
pretreated CDCs did not (Figures 4C and 4D). When we adop-
tively transferred PSA-treated WT CD4+ T cells but not DCs,
CD4+ T cell recipients were not protected (Figure 4E). This result
indicated that CD4+ T cells require DCs previously exposed to
PSA to mediate protection in vivo.
To demonstrate that adoptively transferred DCs were not the
source of IL-10 required for protection, we transferred 1–1.5 3
105 PSA-pretreated WT BMPDCs to IL-10/ mice and
challenged them with TNBS; no significant protection occurred
(Figure 4F). To confirm the specificity of PSA-mediated protec-
tion, we pretreated BMPDCs with a control non-zwitterionic
polysaccharide—type II group B streptococcal polysaccha-
ride—rather than PSA. GBSII polysaccharide-treated PDCs
failed to confer protection (Figure 4G).
To assess whether the lack of protection by low-dose PSA-
treated CDCs was due to failure of adoptively transferred
CDCs to localize in the gut and gut-associated lymphoid tissue,
we transferred unsorted donor PSA-pretreated (in vitro) BMDCs
from CD45.1+ B6 mice to CD45.2+ B6 recipients and deter-
mined the cells’ distribution. BMDCs localize and function in
MLNs when transferred intraperitoneally (i.p.) (Creusot et al.,
2009). We found varying quantities of donor PDCs and CDCs
in spleen, MLNs, and colon of recipient mice after 48 hr and
even 9 days (Figure S3). Thus, failure of CDCs to localize to gut
tissues does not explain poor function in the adoptive transfer
model. In fact, CD11c microbead-purified BMDCs—a popula-
tion that consists primarily of CDCs—are protective at a higherHost & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inc. 415
Figure 3. PDCDepletion Abrogates PSAProtection in a TNBSColitis
Model
PDC depletion by DT administration (200 ng/dose, 6 doses) to BDCA2-DTR
mice before inflammation onset inhibits PSA-mediated protection. Boxplots
show median (horizontal bar inside box) and quartile distributions in the TNBS
model. Left and right panels show colitis scores with and without DT,
respectively. Each dot in the boxplots represents an individual mouse.
Scores were assessed for statistical significance by two-tailed nonparametric
Mann-Whitney test. **p < 0.01; ns, not significant. See also Figure S2.
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attributable to PDCs, but PDCs are certainly significantly more
efficient at conferring protection than CDCs, especially in low
numbers.
PDCs and CDCs Vary in Response to PSA
We reported that proinflammatory cytokines tumor necrosis
factor a (TNF-a) and IL-12/IL-23 are liberated by unsorted DCs
after PSA stimulation (Wang et al., 2006). Both cytokines are
implicated in inflammatory bowel disease in humans and mouse
models (Bouma and Strober, 2003). We studied their secretion
in PDCs and CDCs after incubation with PSA. In response
to PSA, CDCs but not PDCs liberated TNF-a and IL-12/IL-23
(Figures 5A and 5B). We cocultured these DC subsets with
splenic CD4+ T cells, with or without PSA. In both settings,
CDCs induced higher IL-10 production by CD4+ T cells than
did PDCs (Figure 5C). However, PSA-induced IL-10 production
by CD4+ T cells, as indicated by the fold increase of IL-10 (ratio
of the cytokine level detected with PSA to that without), was
significantly higher when T cells were cultured with PDCs rather
than CDCs (Figure 5C). These results show greater specificity
of PDCs than CDCs in induction of IL-10 and are consistent
with the greater observed ability of PDCs to confer protection.
Enhanced TLR2 Expression on PDCs and Association
of PDCs with TLR2-Dependent PSA Protection
The presence of TLR2 on APCs is reportedly essential for PSA
stimulation of interferon g (IFNg) production by CD4+ T cells
(Round et al., 2011; Wang et al., 2006). PDCs reportedly mediate
immunoregulation both in vitro and in vivo as well as the
response to viral and some bacterial nucleic acid antigens via
TLRs 7, 8, and 9 (Swiecki and Colonna, 2010), but whether
they play a role in TLR2-dependent immune responses is
unknown. Tracking PDCs in MLNs and spleen through SH416 Cell Host & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inexpression without other stimulation, we found higher-frequency
TLR2 expression in PDCs from MLNs than in splenic PDCs
(Figure S4A). Our results indicated the need to further seek a
TLR2-dependent PDC mechanism prompting PSA-mediated
immunoregulation. PDC-mediated immunoregulation has not
previously been linked to the microbiome.
We investigated whether TLR2 provides a pathway in PDCs
for invocation of immunoregulatory molecules in CD4+ T cells.
Coculture of PDCs or CDCs with CD4+ T cells showed a depen-
dence of IL-10 production by CD4+ T cells on TLR2 expression
by PDCs, but not by CDCs (Figure 6A). PDCs can be character-
ized by specific surface markers, such as SH and PDCA-1.
Induction of TLR2+ PDCs (Figures 6B and S4B), but not CDCs
(Figures 6C and S4B), increased significantly when BMDCs
were incubated with PSA rather than without it. Other TLR2
ligands (e.g., Pam3CSK4, FSL-1) induced TLR2 in both PDCs
and CDCs. Another reported TLR2 agonist, lipomannan from
Mycobacterium smegmatis, failed to significantly induce TLR2
in any DC subset beyond control levels. In another unique aspect
of PSA-PDC interaction, PDCs treated with PSA but not with
other TLR2 ligands induced significantly higher IL-10 production
by CD4+ T cells than occurred in the respective CDC-containing
wells (Figure 6D). This finding strongly suggests that immuno-
regulatory effects of PSA-treated PDCs on CD4+ T cells are
not limited to TLR2 ligation and that additional signaling path-
ways are required.
Our comparison of mice from WT and TLR2/ backgrounds
in the TNBS colitis model revealed a failure of PSA to confer pro-
tection in the TLR2/ background (Round and Mazmanian,
2010) (Figure S4C). Neither the significant reduction in CD11b+
CD11c cell frequency in colonic LP nor the augmented SH
expression seen in WT mice after PSA treatment was seen in
TLR2/ mice (Figures 6E and 6F).
Central Role of Cognate PDC-CD4+TCell Interactions in
PSA-Mediated Immunoregulation In Vitro and In Vivo
DCs reportedly use several strategies to induce immunoregu-
latory activity in CD4+ T cells (Maldonado and von Andrian,
2010). We isolated PDCs fromBMDCs and examined two known
molecular strategies by coculture. First, we assessed the use of
indoleamine 2,3-dioxygenase (IDO) to break down tryptophan
into metabolites that can activate immunoregulatory functions
in CD4+ T cells (Sharma et al., 2007). After addition of 1-
methyl-D-tryptophan (an inhibitor of IDO) to PDC-CD4+ T cell
coculture, IL-10 levels were not perturbed, a result indicating
that this pathway does not participate in PSA-mediated immuno-
regulation (Figure S5A). Second, we explored DC antigen pre-
sentation to CD4+ T cells. To determine whether PSA-mediated
cognate DC-CD4+ T cell interactions are essential for immuno-
regulation, we examined the requirement for major histocompat-
ibility class II (MHCII) involvement (usually referred to as signal 1)
and costimulation (signal 2). We determined IL-10 production in
PDC-WT CD4+ T cell coculture, comparing PDCs from WT and
MHCII/ mice (Figure 7A). IL-10 production was substantially
lower withMHCII/ PDCs, and these cells failed to confer pro-
tection when pretreated with PSA and adoptively transferred to
WT mice in the TNBS-induced colitis model (Figure 7B).
To investigate the role of signal 2, we monitored expression of
the inducible costimulator ligand (ICOSL) in BMPDCs culturedc.
Figure 4. Adoptive Transfer of PSA-Treated PDCs Protects Mice in a TNBS Colitis Model
(A) Protection was seen with oral PSA treatment (100 mg/dose).
(B) Colitis scores of WT mice after treatment with CD11c+ BMDCs show protection following adoptive transfer of the higher of two doses of PSA-pretreated,
CD11c microbead-selected BMDCs (6–6.53 105/dose, 2 doses; PSA-DC hi) but not the lower dose (1–1.53 105/dose, 2 doses; PSA-DC lo) when results were
compared to those with the respective PBS-pretreated BMDCs.
(C) Protection was seen with adoptively transferred lower-dose PSA-pretreated PDCs when results were compared to those with PBS-pretreated PDCs.
(D) No protection was seen with low-dose PSA-pretreated CDCs when results were compared to those with PBS-pretreated CDCs.
(E) PSA-pretreated CD4+ T cells (5 3 105/dose, 2 doses) did not protect mice when results were compared to those with PBS-pretreated CD4+ T cell controls.
(F) After adoptive transfer to IL-10/ mice, low-dose PDCs from WT mice pretreated with PSA or PBS failed to confer significant protection.
(G) Pretreatment of PDCs with a control polysaccharide (type II polysaccharide from group B Streptococcus) failed to protect mice from TNBS-induced colitis
after adoptive transfer. Each dot represents one mouse. Scores were assessed for statistical significance by two-tailed nonparametric Mann-Whitney test.
*p < 0.05; **p < 0.01; ns, not significant. See also Figure S3.
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in SH+PDCA-1+CD11c+ PDCs was significantly higher in PSA-
containing wells than with any other treatment (Figures 7C and
S5C). CD4+ T cell production of IL-10 decreased substantially
in coculture with PDCs from ICOSL/ or CD86/ mice, but
not CD80/ mice (Figures 7D, 7E, and S5B). ICOS and CD28
are the receptors on CD4+ T cells that interact with ICOSL and
CD86 on APCs, respectively (Greenwald et al., 2005). Accord-
ingly, in coculture with WT PDCs, IL-10 production was sig-
nificantly lower with CD4+ T cells from ICOS/ or CD28/
mice than with CD4+ T cells from WT mice (Figure 7F). Thus,
cognate interactions involving MHCII and costimulation by
PSA-activated PDCs are required for initiation of IL-10 produc-Celltion by CD4+ T cells. PSA’s ability to stimulate cognate interac-
tions explains why pure TLR2 ligands, while inducing high-level
expression of TLR2 in PDCs, fail to stimulate higher-fold in-
creases in IL-10 production by CD4+ T cells in coculture (Figures
6B and 6D). The importance of costimulation in PSA-treated
PDCs was further validated by a lack of protection when PSA-
treated WT BMPDCs were transferred to ICOS/ mice in the
TNBS colitis model (Figure 7G); this result contrasted with that
in WT recipients (Figure 4C).
We determined the state of PDC activation during active
TNBS-induced colitis after oral treatment of mice with PSA
or PBS. In diseased TNBS + PBS mice, the PDCs remaining
after drastic reduction in PDCs (Figure 2A) retained theirHost & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inc. 417
Figure 5. PSA Differentially Affects Diverse DC Subsets
(A and B) Levels of proinflammatory cytokines TNF-a (A) and IL-12/IL-23 (B)
were measured in supernatants of monocultures containing PDCs or CDCs
(53 104 cells/ml) that were incubated for 24 hr with or without PSA (100 mg/ml).
Data represent two experiments.
(C) IL-10 liberation from CD4+ T cells cocultured with CDCs and PDCs. IL-10
levels were measured by ELISA of culture supernatants of PDCs or CDCs
cocultured with CD4+ T cells for 5 days in the presence of anti-CD3.
Cocultures were either treated or not treated with PSA (50 mg/ml). Horizontal
bars show the fold increase in mean IL-10 production in PSA-treated
cocultures. Data represent the average of seven independent experiments.
Error bars indicate SEM values. See also Figure S6.
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age of marker-bearing PDCs (i.e., the proportion of antigen-
presenting molecule-bearing PDCs among total PDCs) was
actually higher in PBS-treated mice than in PSA-treated animals.
However, when absolute numbers of antigen-presenting mole-
cule-bearing PDCs were determined, PSA-protected mice
(TNBS + PSA) had higher counts of active PDCs than TNBS +
PBS mice. Expression of markers as represented by GMFI
did not change appreciably in the treatment groups (Figures
S5D–S5G). Finally, we investigated whether adaptive immune
costimulation-dependent cognate interaction is essential for
PSA-mediated immunoregulation in vivo. We treated mice with
inhibitory mAb to either ICOSL or CD86 or with an isotype control
antibody before intrarectal administration of TNBS. The mice
received PBS or PSA by oral gavage. The lack of change in colitis
scores of mice treated with mAb and PBS indicated that inhibi-
tion by blocking antibodies did not alter the disease process.
Mice treated with PSA and isotype control antibody had sig-
nificantly lower colitis scores than mice in the corresponding
PBS-treated group. Inhibition of CD86, however, completely
negated PSA protection. Inhibition of ICOSL had an intermediate
effect, with colitis scores lower than those in CD86-inhibited
mice but higher than those in isotype controls (Figure 7H). To
further investigate ICOSL participation, we compared PSA’s
protective effect inWT and ICOSL/mice. PSA’s failure to pro-
tect ICOSL/ mice contrasted with PSA-mediated protection418 Cell Host & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inin WT animals (Figure 7I). Taken together, our data show the
importance of cognate PDC-CD4+ T cell interactions mediated
by MHCII and costimulatory molecules on PDCs in PSA-medi-
ated protection.
DISCUSSION
B. fragilis PSA provides a unique opportunity to explore immuno-
regulation mediated by commensal microbes on a molecular
level. We have found that in vivo PSA-mediated protection in
an inflammatory bowel disease model requires DC involvement
and that one DC subset, PDCs, is particularly active. CDCs
and PDCs arise from common precursors that have lost the
potential to differentiate into monocytes and macrophages
(Miller et al., 2012). PDCs rank high in the tolerogenic DC hierar-
chy, with a greater capacity to generate Tregs (Maldonado and
von Andrian, 2010), but their role in containing colonic inflam-
mation has not been described.
In adoptive transfer experiments, we used BMPDCs rather
than primary tissue (e.g., MLN)-derived murine PDCs. We
acknowledge that the two may behave differently. To establish
a direct link between PSA and PDCs, we first showed the
dynamics of PDCs (absolute numbers, frequency, and GMFI
of SH) in MLNs and colonic LP in TNBS-induced colitis. As a
proof of principle, we validated PSA’s direct influence on
PDCs, using BMPDCs both in vitro and in vivo. PDCs preincu-
bated with PSA were protective in TNBS colitis after adoptive
transfer; equivalent numbers of PSA-preincubated CDCs
were not. This result suggests that PDCs may be unique in
the ability to generate PSA-induced immunoprotection. The
lack of induction of proinflammatory cytokines after PSA treat-
ment and the significant ability to induce the PSA-dependent
anti-inflammatory cytokine IL-10 in CD4+ T cells may account
for fewer PDCs than CDCs mediating protection after adoptive
transfer. PDCs generate IFNg+IL-10+CD4+ T cells in vivo
through Notch signaling (Kassner et al., 2010). That PSA in-
duces the generation of both IFNg and IL-10 supports PDC
involvement in PSA-mediated immunoregulation. Although a
role for other DC subsets in PSA function cannot be ruled
out, our results indicate that PSA’s effect on PDCs, with conse-
quent augmentation of Treg function, represents a central host-
microbial strategy in the gut that limits the extent and severity
of inflammatory diseases.
Molecular mediators in murine and human PDCs that report-
edly generate Tregs include ICOSL, IDO, retinoic acid, CD40L,
D-like ligand 4 (a Notch ligand), and MHCII (Chen et al., 2008;
Colvin et al., 2009; Fallarino et al., 2004; Irla et al., 2010; Ito
et al., 2007; Kassner et al., 2010; Lombardi et al., 2012; Manches
et al., 2008; Martı´n-Gayo et al., 2010; Sharma et al., 2007). Some
of these mediators may act in tandem to control pathologic
inflammation. PSA uses some of these mediators in PDCs
(e.g., MHCII, ICOSL, CD86), but not others (e.g., IDO). Our
data support the hypothesis that PSA—acting through DCs,
particularly PDCs—is presented to T cells and that its presenta-
tion requires both signals 1 and 2. PSA-mediated induction
of IFNg in CD4+ T cells in vitro depends on synergy of TLR2
activation and antigen presentation pathways (Wang et al.,
2006). We have reported that PSA is a unique polysaccharide
presented in the context of MHCII by APCs (Cobb et al., 2004).c.
Figure 6. PDCs Have an Immunoregulatory Phenotype that Is TLR2 Dependent
(A) The presence of TLR2 on PDCs (but not on CDCs) augments PSA-generated IL-10 production by CD4+ T cells, as measured by ELISA (average of
3 experiments).
(B and C) Elevated frequency of TLR2+ PDCs (SH+PDCA-1+CD11c+) (B), but not of TLR2+ CDCs (SHCD11c+) (C), after PSA treatment (60 mg/ml). Pam3CSK4
(PAM, 0.1 mg/ml) and FSL-1 (0.1 mg/ml), but not lipomannan (LM-MS, 10 ng/ml), augment both TLR2+ PDCs and TLR2+ CDCs. Data are from two independent
experiments.
(D) PDCs treated with PSA but not with other TLR2 ligands show a significant increase (as measured by ELISA) in fold induction of IL-10 production by CD4+
T cells over that seen with PSA-treated CDCs (average of three independent experiments). Error bars in (A)–(D) indicate SEM values.
(E and F) PSA-induced diminution of colonic lamina propria CD11b+CD11c cells (E) and augmentation of GMFI of SH in MLNs (F) in TNBS-induced colitis in
WT mice but not TLR2/mice, a similar situation. Unpaired Student’s t test: *p < 0.05; **p < 0.01; ns, not significant. Error bars indicate SEM values. See also
Figure S4.
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development, the immunostimulatory activity of PSA and
related zwitterionic polysaccharides depends on costimulatory
molecules of the B7 family (Stephen et al., 2005). Immuno-
protection by PSA in those models also depends on ICOS-
ICOSL interaction (Ruiz-Perez et al., 2005), although a specific
APC mediating these interactions with T cells was not identi-
fied. Antigen presentation and costimulation alone are not
sufficient for PSA-induced immunoprotection; innate immune
pathways, particularly those mediated through TLR2, are also
required. PSA-mediated induction of T cell immunoregulatory
activity illustrates innate-adaptive immune system cooperation.
PSA’s induction of its immunosensitive receptor TLR2 on
PDCs opens avenues for study of other commensal microbial
molecules in terms of reactivity to PDCs and subsequent
immunoprotection.
A major feature of PDCs after TLR7/TLR9-mediated activation
is type 1 IFN secretion, a response usually culminating in an
immunity-enhancing proinflammatory outcome (Swiecki et al.,
2010). However, TLR9 activation-mediated type 1 IFNs are pro-
tective in experimental colitis (Katakura et al., 2005). Thus, PDCs
may promote protection against colitis via type 1 IFN secretion.
We considered this possibility but did not detect IFNa secretion
from BMDCs or isolated PDCs in the presence of PSA in vitro
(Figure S6). We observed an association of SH expression on
PDCs with protection. In PDCs, SH activates DAP-12-generated
immunoregulatory pathways that oppose type 1 IFN-drivenCellproinflammatory pathways initiated by TLR9 ligation (Blasius
et al., 2006). Whether association of SHwith colitis has biological
relevance must be examined in future studies.
One pathway by which PDCs may help protect animals
against inflammation is promotion of tolerance to pathology-
inducing antigens. PDCs from MLNs and liver play important
roles in oral tolerance to antigens and haptens. Tolerance in
this setting is due to deletion of antigen presentation-induced
anergic or antigen-specific T cells (Goubier et al., 2008). We
wonder whether PDCs can play such a role in mounting
tolerance to TNBS-haptenized antigens so that, in the absence
of PDCs, tolerogenic potential is compromised, and this
deficiency manifests as augmented inflammation exceeding
PSA’s capacity to mediate protection. Indeed, PDCs are tolero-
genic to antigen-induced immune pathology in EAE and airway
hyperreactivity (Irla et al., 2010; Lombardi et al., 2012) and play
a role in promoting central tolerance to peripheral antigens
(Hadeiba et al., 2012). Of interest is whether the ‘‘human micro-
bial education’’ of this vital DC subset, which includes induc-
tion of innate immune receptor TLR2 and communication with
CD4+ T cells through costimulatory molecules and which leads
to immunoregulation, has important clinical consequences.
Our observation that adoptively transferred PSA-treated PDCs
confer protection may serve as a ‘‘proof of concept’’ for future
PDC-dependent therapeutics.
Herein we show that PSA, the archetypical immunoregulatory
microbial molecule from the microbiome, requires both innateHost & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inc. 419
Figure 7. Cognate Interactions Are Essential for PSA-Mediated Generation of IL-10 In Vitro and for Protection in the TNBS Colitis Model
(A) WT CD4+ T cells cocultured with PDCs from WT andMHCII/mice were compared. Cocultures with WT PDCs had significantly higher levels of IL-10 than
those with MHCII-deficient PDCs.
(B) Adoptive transfer of PSA-pretreated BMPDCs from MHCII/ mice (1.5 3 105/dose, 2 doses) did not confer significant protection to WT mice.
(C) Bone marrow-derived PDCs (SH+PDCA-1+CD11c+; gating used for evaluation) included a significantly higher frequency of ICOSL+SH+ cells when treated
with PSA (60 mg/ml) than when treated with other TLR2 ligands (Pam3CSK4 [PAM], 0.1 mg/ml; FSL-1, 0.1 mg/ml; and lipomannan [LM-MS], 10 ng/ml) or left
untreated (medium control). Bar graph shows average of five independent experiments.
(D and E) Cocultures of WT CD4+ T cells with PDCs from ICOSL/mice (D) or CD86/mice (E) produced significantly less IL-10 than cocultures of WT CD4+
cells with WT PDCs.
(F) Enhanced ability of PDCs fromWTmice to stimulate IL-10 productionmore strongly inWTCD4+ T cells than in CD4+ T cells from ICOS/ orCD28/mice.
Data are the average of two independent experiments.
(G) Adoptive transfer of PSA-pretreated WT PDCs did not confer protection in ICOS/ recipients.
(H) Anti-CD86 IgG and anti-ICOSL IgG blocked PSA-mediated protection and significantly reduced protection from that in IgG isotype control-treated mice.
(I) WT mice, but not ICOSL/mice, were significantly protected after oral PSA treatment. Data shown in (A) and (C)–(F) were analyzed by unpaired Student’s t
test. *, **, and *** denote p < 0.05, p < 0.01, and p < 0.001, respectively. Clinical scores shown in (B) and (G)–(I) were assessed for statistical significance by two-
tailed nonparametric Mann-Whitney test. *p < 0.05; **p < 0.01; ns, not significant. Each dot represents one mouse. Error bars indicate SEM values. See also
Figure S5.
Cell Host & Microbe
Cellular Mechanisms in PSA-Mediated Protectionand adaptive immunity to generate protection; that DCs are
needed in initiating production of IL-10—a critical immuno-
modulator in this process—by CD4+ T cells; that PDCs are
more efficient and specific than CDCs in initiating this process;420 Cell Host & Microbe 15, 413–423, April 9, 2014 ª2014 Elsevier Inthat PDCs play a fundamental role in commensal molecule-
CD4+ T cell interaction; and that this interaction results in
immunoregulation—a biological outcome critical to health. This
mechanistic insight has potential therapeutic utility and offersc.
Cell Host & Microbe
Cellular Mechanisms in PSA-Mediated Protectiona pathway by which to search for therapeutic molecules ex-
pressed by commensals.
EXPERIMENTAL PROCEDURES
Animals
Unless stated otherwise, all mice were CD45.2+ C57BL/6 and were purchased
from Jackson Laboratory (Bar Harbor, ME) or Taconic Farms (Germantown,
NY). All experiments on animals were approved by the Harvard Medical
Area Standing Committee on Animals (animal protocol numbers 8604781
and 04591).
PSA Extraction
PSA was purified from B. fragilis mutant strain D44 (Tzianabos et al., 1992).
No LPS was detectable in the PSA preparation by gel electrophoresis, 1H-
NMR analysis, or endotoxin assay.
PDC and CDC Preparation
PDCs were isolated from 10-day-old BMDCs by positive selection (mPDCA-1
microbeads; Miltenyi Biotec, Boston, MA) or negative selection (PDC Isolation
Kit II; Miltenyi). The flowthrough of the positive-selection column was further
positively selected with CD11c microbeads to obtain CDCs. The cells sepa-
rated out at each step were scrutinized with flow cytometry, which revealed
a difference of 6- to 11-fold in PDC frequency between the PDC-enriched
fraction (% SH+CD11c+ [mean ± SD]: 36.02 ± 2.2 by positive selection,
69.15 ± 7.07 by negative selection) and the CDC fraction (% SH+CD11c+:
6.71 ± 1.36).
DC-CD4+ T Cell Coculture
DCs and CD4+ T cells were isolated from spleens of untreated mice with
CD11c microbeads (Miltenyi) and a Mouse T Cell CD4 Subset Column Kit
(R&D Systems), seeded simultaneously (2 3 104 and 1 3 105, respectively),
and cultured with PSA (50 mg/ml) and anti-CD3 (1 mg/ml) for 5 days at 37C
in 5% CO2 in 96-well round-bottom plates. Conditions of PDC/CDC-CD4+
T cell coculture were similar to those of splenic DC-CD4+ T cell coculture.
TNBS-Induced Colonic Inflammation and PSA Treatment
Animals were bought at the age of 5 weeks and maintained in our facility for
at least 1 week before experiments. Colitis was induced with TNBS (Sigma) as
previously reported but with some modifications (te Velde et al., 2006; Wirtz
et al., 2007). Mice were presensitized with 1% TNBS in acetone-olive oil
(4:1) buffer, which was placed on the shaved back; 7 days later, mice received
TNBS in 50% ethanol (145–160 mg of TNBS, or 3% wt/vol for a 20 g mouse)
intrarectally (3.5-Fr catheter; Instech Solomon, Plymouth Meeting, PA).
Controls were treated similarly but without TNBS. On alternate days before
TNBS administration, mice received six oral doses of PSA (50–100 mg in
200 ml of PBS/dose) or PBS. Mice were weighed each day thereafter and
sacrificed after 3–4 days. Tissue samples were collected for flow cytometry
and histologic analysis after scoring of gross clinical findings. The colitis
score was calculated as the sum of the percentage of weight lost (0%–
4% = 0, >4%–10% = 1, >10%–15% = 2, >15%–20% = 3, and >20% = 4),
stool softness (scored blindly; 0 = well-formed hard stool, 1 = soft stool,
2 = very soft stool with fluid, and 3 = completely diluted stool), apparent
colonic thickness (scored blindly; 0 = visually normal colon, cut with no resis-
tance; 1 = slightly enlarged-diameter colon, cut with no resistance; 2 =
enlarged-diameter colon, cut with little resistance; and 3 = enlarged-diameter
colon, cut only with great resistance), and histopathology (scored blindly; 0, 1,
2, and 3 = no, mild, moderate, and severe inflammation; 4 = severe inflamma-
tion and necrosis).
Adoptive Transfer
CD11c+ whole DCs, PDCs, and CDCs were isolated from BMDCs by a mag-
netic bead-based method involving CD11c microbeads, a PDC Isolation Kit II,
mPDCA-1 microbeads followed by CD11c microbeads, respectively, and
splenic CD4+ T cells with CD4 (L3T4) microbeads (Miltenyi). After incubation
in culturemediumwith PSA (300 mg/ml) or PBS for 6 hr at 37C in 5%CO2, cells
were washed and resuspended in cold PBS for adoptive transfer. CD11c+Cellwhole DCs (high dose: 6–6.5 3 105/dose; low dose: 1–1.5 3 105/dose),
PDCs (1–1.5 3 105/dose), CDCs (1–1.5 3 105/dose), or CD4+ T cells (5 3
105/dose) were transferred i.p. to recipients in 300 ml in PBS. Injections were
given 12 and 2 days before intrarectal administration of TNBS. All mice
received PBS by mouth. Controls included mice given oral PSA (100 mg/ml)
along with i.p. PBS and intrarectal TNBS. TNBS-untreated controls received
PBS both orally and i.p.EAE Induction and PSA Treatment
Female SJL/J mice (Jackson Laboratory) were purchased at 6 weeks of age
and maintained in our facility for at least 1 week before experiments. Mice
were treated with PSA, and EAE was induced with PLP as previously reported
but with some modifications (Ochoa-Repa´raz et al., 2010). In brief, mice
received 100 mg of purified PSA by oral gavage every 3 days, starting
6 days before EAE induction and ending 9 days afterward. Mice were chal-
lenged subcutaneously with 250 mg of PLP 139-151 (Peptides International,
Louisville, KY) in 250 ml of complete Freund’s adjuvant (Sigma) fortified with
Mycobacterium tuberculosis H37 Ra antigen (5 mg/ml; BD, Difco). On days
0 and 2, challenged mice received 250 ng of Bordetella pertussis toxin i.p.
(List Biological, Campbell, CA). Disease progression was scored daily up to
day 14 after PLP administration (0 = no clinical signs; 0.5, partially limp tail;
1, paralyzed tail; 2, loss of coordination and hind-limb paresis; 2.5, paralysis
of one hind limb; 3, paralysis of both hind limbs; 3.5, paralysis of both hind
limbs and forelimb weakness; 4, forelimb and hind-limb paralysis; and 5,
moribund state) (Stromnes and Goverman, 2006). Mice scoring R4 were
sacrificed. Spinal cord histopathology scores were assessed blindly (0, 1, 2,
and 3 = no, mild, moderate, and severe inflammation). EAE scores were
calculated as the sum of disease progression scores at death or sacrifice
and corresponding spinal cord histopathology scores. For percentage sur-
vival, eachmouse was scored 1 when found dead or ill enough to be sacrificed
or 0 in all other cases. For severity of illness, each mouse was scored 1 at first
symptom detection or when found dead before symptom detection. In all
other cases, the score was 0.Histology
Mouse tissues were fixed and stored in Bouin’s solution (VWR Scientific, West
Chester, PA). Fixed tissues were embedded in paraffin, sectioned, mounted
onto slides, and stained with hematoxylin and eosin. Sections were assessed
blindly by a pathologist (Dr. R.T. Bronson, Harvard Medical School).Statistical Analysis
All p values except clinical scores and survival rates were calculated by un-
paired two-tailed Student’s t test. For comparisons of clinical scores, the
two-tailed nonparametric Mann-Whitney test was used. To calculate p values
for survival rates, the log-rank test was used.SUPPLEMENTAL INFORMATION
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